The loss of Sangamo Therapeutics under GAAP for 9 months of 2020 amounted to $80.447 million, which is 19.5% lower compared to $99.92 million in the previous year. Revenue increased 94.2% to $92.392 million, compared to $47.577 million a year earlier.
The loss of Sangamo Therapeutics under GAAP for 9 months of 2020 amounted to $80.447 million, which is 19.5% lower compared to $99.92 million in the previous year. Revenue increased 94.2% to $92.392 million, compared to $47.577 million a year earlier. 
investor.sangamo.com
English (US) 